title: Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.
abstract: EORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of CanadaGBM, glioblastomaOS, overall survivalPFS, progression-free survivalSEER, Surveillance, Epidemiology, and End ResultsTMZ, temozolomide.
authors.affiliation: *Department of Neurological Surgery, ‡Department of Epidemiology and Biostatistics, and §Department of Neurology, University of California, San Francisco, San Francisco, California.
authors.forename: Seunggu J
authors.initials: SJ
authors.lastname: Han
authors.forename: Dario J
authors.initials: DJ
authors.lastname: Englot
authors.forename: Harjus
authors.initials: H
authors.lastname: Birk
authors.forename: Annette M
authors.initials: AM
authors.lastname: Molinaro
authors.forename: Susan M
authors.initials: SM
authors.lastname: Chang
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Clarke
authors.forename: Michael D
authors.initials: MD
authors.lastname: Prados
authors.forename: Jennie W
authors.initials: JW
authors.lastname: Taylor
authors.forename: Mitchel S
authors.initials: MS
authors.lastname: Berger
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Butowski
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D014481:United States